The U.S. Food and Drug Administration (FDA) is currently looking into a California-based company’s microdosing gummies and candies after reports emerged of 12 illnesses linked to their products in various states. These incidents have resulted in 10 hospitalizations, but fortunately, no deaths have been reported so far.
The brand in question, Diamond Shruumz, headquartered in Santa Ana, has been tied to these illnesses across eight states, including Alabama, Arizona, Indiana, Kentucky, Missouri, Nevada, Pennsylvania, and South Carolina. The symptoms reported by those affected range from seizures to abnormal heartbeats and nausea/vomiting.
The FDA is actively collaborating with poison control centers, as well as local and state authorities, to uncover the root causes behind these illnesses. Consumers are strongly advised to discard any Diamond Shruumz products they may have purchased to prevent further incidents, especially parents who should ensure that children and teens do not have access to these items due to their appealing packaging.
Diamond Shruumz markets its cannabis microdosing products as a “soul-candy,” which can be bought for approximately $25-$30 on their website. The company’s tagline invites consumers to explore microdosing as a way to enhance their experiences.
Microdosing typically involves taking a fraction of the full dose of a psychoactive substance to avoid intense effects associated with higher doses. Supporters claim that microdosing can positively impact creativity, mood, and productivity.
A study conducted by Harvard Medical School in September 2022 emphasized the complexities of assessing the efficacy of microdosing due to variations in individual responses to even small doses.
Moreover, LSD and psilocybin, substances commonly used in microdosing, may lead to physiological tolerance over time. It’s vital to acquire precise dosing information from reputable sources, as regulations and research remain limited.
Recent studies have explored the effects of microdosing on psychedelics like psilocybin mushrooms, with mixed results. However, the exact benefits of microdosing largely hinge on individual expectations and responses.